Nasdaq
$0.9112▼ 6.20%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $65.9MShares out 72.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 9.14Pre-market26.09.14 19:006-KKey event#●●●#●●●
Cellectis S.A.
Cellectis has confirmed a strategic transformation into an in vivo gene editing company, discontinuing the development of its cell therapy candidates, lasme-cel and eti-cel. The company is realigning its operations to extend its cash runway into H2 2028 while focusing on advancing its .HEAL-101 and .HEAL-201 programs. Trading of the company's ordinary shares on Euronext Growth will be temporarily halted on September 14, 2026, starting at 9:00 a.m. CET.…more
$0.9112-6.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.11After-hours26.09.12 05:356-KKey event
Cellectis S.A.
Cellectis announced that it will host a conference call and webcast on September 14, 2026, to provide a business update. The event will be held in both English and French, and investors can participate via the provided webcast links or conference call phone numbers.…more
$0.9112-6.20%vs prev closeView filingShare - 9.11After-hours26.09.12 05:306-K/AKey event
Cellectis S.A.
Cellectis S.A. reported its financial results for the first half of 2026, with revenues of $11.006 million and a net loss of $39.584 million. While revenues decreased compared to the same period last year, the net loss showed a slight improvement, and the company held $35.59 million in cash and cash equivalents as of June 30, 2026.…more
$0.9112-6.20%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6After-hours26.10.07 05:30#●●●
Cellectis Reports Monthly Share Capital and Voting Rights
Cellectis has disclosed its total number of shares and voting rights as of the end of September in accordance with French financial market regulations. This is a routine regulatory filing and does not have a direct impact on the stock price.…more
$0.9112-6.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.14Regular26.09.14 22:39
●●●●●●●● ●●●●● ●●●●●●
Cellectis is shifting its strategic focus toward in vivo gene editing while discontinuing its allogeneic CAR T-cell programs. The market reacted negatively to the restructuring news, leading to a significant decline in the company's stock price.…more
$0.9112-6.20%vs prev closeShareBenzinga - 9.14Overnight26.09.14 16:59
●●●●●●●● ●●●●● ●●●●●●
Cellectis is discontinuing certain cell therapy programs to prioritize its in vivo gene editing pipeline. This strategic realignment aims to extend the company's cash runway through the second half of 2028.…more
$0.9112-6.20%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report